Drug Approval News: The FDA has approved JNJ’s Rybrevant® (Amivantamab-vmjw plus Lazertinib) as a first line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer.
Lazertinib is a tyrosine kinase inhibitor targeting EGFR with activating mutations including T790M, Del19 and L858R.
Focus Biomolecules can supply Lazertinib for research applications. Contact us for a rapid quotation.
